covid
Buscar en
Revista Colombiana de Cancerología
Toda la web
Inicio Revista Colombiana de Cancerología Radioterapia conformada en pacientes con cáncer de próstata Experiencia de tre...
Journal Information
Vol. 13. Issue 3.
Pages 124-133 (January 2009)
Share
Share
Download PDF
More article options
Vol. 13. Issue 3.
Pages 124-133 (January 2009)
Full text access
Radioterapia conformada en pacientes con cáncer de próstata Experiencia de tres años en el Instituto Nacional de Cancerología de Colombia
Conformal Radiotherapy in Patients with Prostate Cancer A Three-Year Study at the National Cancer Institute of Colombia
Visits
2906
Rosalba Ospino Peña1,
Corresponding author
rospino@cancer.gov.co

Correspondencia Rosalba Ospino, Grupo de Radioterapia, Instituto Nacional de Cancerología. Av. 1ª No. 9-85, Bogotá, Colombia.
, Ilse Vásquez Aponte1,2, Ricardo Cendales1,2, Franz Usuga1,2
1 Instituto Nacional de Cancerología, Bogotá, Colombia
2 Pontificia Universidad Javeriana, Bogotá, Colombia
This item has received
Article information
Resumen
Objetivo

Describir las características clínicas y demográficas y la supervivencia libre de cualquier evento y toxicidad en pacientes con cáncer localizado de próstata, tratados con radioterapia conformada en el Instituto Nacional de Cancerología.

Métodos

Se revisaron los registros de pacientes tratados con radioterapia conformada entre enero del 2003 y diciembre del 2006. Se realizaron análisis descriptivos y se analizó la supervivencia mediante el método de Kaplan-Meier.

Resultados

Se trataron 196 pacientes y se incluyeron 114 en el análisis. La mediana de seguimiento fue de 14,4 meses. La supervivencia libre de enfermedad, a 30 meses, fue de 74%. Se presentaron seis eventos en el grupo de alto riesgo y tres en el de riesgo intermedio; no se presentaron eventos en el de bajo riesgo. La supervivencia libre de recaída fue de 100%, 73% y 63% para los riesgos bajo, intermedio y alto, respectivamente. La toxicidad crónica urinaria no preexistente de cualquier grado fue de 12,8%; la rectal, de 10,8%, y la sexual, de 18,3%.

Conclusiones

El seguimiento fue corto y limita la posibilidad de hacer comparaciones con series internacionales. No se demostraron diferencias estadísticamente significativas en la supervivencia libre de recaída, según grupos de riesgo; sin embargo, los eventos se presentaron acordes con el riesgo. Un tamaño de muestra superior podría haber incrementado la potencia del estudio para detectar estas diferencias. La toxicidad rectal, sexual y urinaria no se midió de manera sistemática, por lo cual los resultados no son concluyentes. Se deben implementar guías para definir el manejo con hormonoterapia.

Palabras clave:
neoplasias de la próstata
radioterapia conformal
Abstract
Objective

To describe clinical and demographic characteristics, event free survival, and the toxicity in prostate cancer patients treated with conformal radiotherapy at the National Cancer Institute of Colombia.

Methods

Case histories of patients treated with conformal radiotherapy between January, 2003 and December, 2006 were reviewed. Descriptive analyses were carried out and a survival analysis was performed with the Kaplan-Meier method.

Results

One hundred and ninety-six patients were treated, 114 of whom were included in the analyses. Median follow-up was 14.4 months. Disease free survival at month 30 was 74%. Six events occurred in the high risk group three in the intermediate risk group, and none in the low risk group. Relapse free survival was 100%, 73% and 67% for the low, intermediate, and high risk groups, respectively. Non pre-existent chronic toxicity of any degree was: 12.8%, urinary; 10.8%, rectal; and 18.3%, sexual.

Conclusions

Follow-up was short and the possiblity of making comparisons with international series was limited. According to risk group, no statistically significant differences were shown for relapse free survival; however, events occurred in accordance with level of risk. A larger sample group could have enhanced the study's potential to detect these differences. Rectal, sexual and urinary toxicities were not measured systematically, hence the results are not conclusive. Guidelines should be adopted for the application of hormonotherapy.

Key words:
Prostate neoplasia
conformal radiotherapy
Full text is only aviable in PDF
Referencias
[1.]
J. Ferlay, F. Bray, P. Pisani, D.M. Parkin.
GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide.
IARC Cancer Base No. 5. version 2, IARC Press, (2004),
[2.]
Piñeros M, Ferlay J, Murillo R. Incidencia estimada y mortalidad por cáncer en Colombia. 1995-1999. Instituto Nacional de Cancerología, Internacional Agency for Research on Cancer y Ministerio de Protección Social. 2005. [Sitio en internet]. Bogotá: Instituto Nacional de Cancerología: 2005. Hallado en http://www.incancerologia.gov.co/documentos/3_20_2007_1_13_22_PM_libro1.pdf. Acceso el 30 de junio de 2008.
[3.]
Murillo RH, Piñeros M, Pardo C, Quintero A. Anuario Estadístico 2006 “Por el control del cáncer”. [Publicación Institucional en Internet]. Bogotá: Instituto Nacional de Cancerología: 2005. http://www.incancerologia.gov.co/documentos/1_3_2008_10_21_58_AM_anuario%20estadistico.pdf. Acceso el 20 de julio de 2008. in press.
[4.]
M. Zelefsky, R. Valicenti, Goodman Karin, C. Perez.
Part I Male genitourinary tumors Chapter 58 Prostate cancer.
Perez C. Principles and practice of radiation oncology, Fourth, Lippincott Williams & Wilkins, (2004), pp. 1698-1701
[5.]
D.P. Dearnaley, V.S. Khoo, A.R. Norman, L. Meyer, A. Nahum, D. Tait, et al.
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial.
Lancet, 53 (1999), pp. 267-272
[6.]
P.C. Koper, J.C. Stroom, W.L. Van Putten, G.A. Korevaar, B.J. Heijmen, A. Wijnmaalen, et al.
Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study.
Int J Radiat Oncol Biol Phys, 43 (1999 Mar 1), pp. 727-734
[7.]
D.P. Dearnaley, M.R. Sydes, J.D. Graham, E.G. Aird, D. Bottomley, R.A. Cowan, et al.
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
Lancet Oncol, 8 (2007 Jun), pp. 475-487
[8.]
A.L. Zietman, M.L. DeSilvio, J.D. Slater, C.J. Rossi Jr., D.W. Miller, J.A. Adams, et al.
Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
JAMA, 294 (2005 Sep 14), pp. 1233-1239
[9.]
S.T. Peeters, W.D. Heemsbergen, P.C. Koper, W.L. Van Putten, A. Slot, M.F. Dielwart, et al.
Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
J Clin Oncol, 24 (2006 May 1), pp. 1990-1996
[10.]
D.A. Kuban, S.L. Tucker, L. Dong, G. Starkschall, E.H. Huang, M.R. Cheung, et al.
Long-term results of the M D. Anderson randomized dose-escalation trial for prostate cancer.
Int J Radiat Oncol Biol Phys, 70 (2008 Jan 1), pp. 67-74
[11.]
República de Colombia. Ministerio de Salud. Resolución 8430 de 1993 (4 de octubre), por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Diario oficial No. 42.247, 9 de enero de 1996.
[12.]
Consensus Statement: Guidelines for PSA following radiation therapy.
American Society for Therapeutic Radiology and Oncology Consensus Panel.
Int J Radiat Oncol Biol Phys, 37 (1997 Mar 15), pp. 1035-1041
[13.]
M. Roach 3rd, G. Hanks, H. Thames, P. Schellhammer, W. Shipley, G. Sokol, et al.
Defining biochemical failure following radiotherapy with or with out hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
Int J Radiat Oncol Biol Phys, 65 (2006 Jul 15), pp. 965-974
[14.]
J.J. Pavy, J. Denekamp, J. Letschert, B. Littbrand, F. Mornex, J. Bernier, et al.
Late Effects Toxicity Scoring: The Soma Scale.
Int. J. Radiation Oncology Biol Phys, 31 (1995 Mar 30), pp. 1043-1047
[15.]
M. Roach, 3rd, C. Marquez, H.S. Yuo, P. Narayan, L. Coleman, U.O. Nseyo, et al.
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
Int J Radiat Oncol Biol Phys, 28 (1994 Jan 1), pp. 33-37
[16.]
A.W. Partin, L.A. Mangold, D.M. Lamm, P.C. Walsh, J.I. Epstein, J.D. Pearson.
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Urology, 58 (2001 Dec), pp. 843-848
[17.]
M.T. Milano, L.S. Constine, P. Okunieff.
Normal tissue tolerance dose metrics for radiation therapy of major organs.
Semin Radiat Oncol, 17 (2007 Apr), pp. 131-140
[18.]
S. Nilsson, B.J. Norlén, A. Widmark.
A systematic overview of radiation therapy effects in prostate cancer.
Acta Oncol, 43 (2004), pp. 316-381
[19.]
F. Leborgne, J.H. Leborgne, B. Zubizarreta, J.D. Leborgne, S. Aguiar, et al.
Cáncer localizado de próstata: Experiencia de diez años con la radioterapia conformal tridimensional.
Rev Med Uruguay, 20 (2004), pp. 193-201
[20.]
M. Zelefsky, Z. Fuks, H. Chan, C. Ling, M. Hunt, S. Leibel.
Ten-year results of dose escalation with 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer.
Int J Rad Oncol Biol Phys, 57 (2003 Oct), pp. S149-S150
[21.]
J.B. Madalinska, M.L. Essink-Bot, H.J. Koning, W.J. Kirkels, P.J. Van der Maas, F.H. Schröder.
Health-Related Quality-of-Life Effects of Radical Prostatectomy and Primary Radiotherapy for Screen-Detected or Clinically Diagnosed localized Prostate Cancer.
J Clin Oncol, 19 (2001), pp. 1619-1628
[22.]
Al. Potosky, W.W. Davis, R.M. Hoffman, J.L. Stanford, R.A. Stephenson, D.F. Penson, et al.
Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study.
Journal of the National Cancer Institute, 96 (2004), pp. 1358-1367
[23.]
D. Kuban, A. Pollack, E. Huang, L. Levy, L. Dong, G. Starkschall, et al.
Hazards of dose escalation in prostate cancer radiotherapy.
Int J Radiat Oncol Biol Phys, 57 (2003 Dec 1), pp. 1260-1268
Copyright © 2009. Instituto Nacional de Cancerología
Download PDF
Article options